Literature DB >> 11358851

Ganglioside G(D2) in small cell lung cancer cell lines: enhancement of cell proliferation and mediation of apoptosis.

S Yoshida1, S Fukumoto, H Kawaguchi, S Sato, R Ueda, K Furukawa.   

Abstract

Expression levels of gangliosides and glycosyltransferase genes responsible for their syntheses in human lung cancer cell lines and a normal bronchial epithelial cell line were analyzed. Both non-small cell lung cancers and small cell lung cancers (SCLCs) mainly expressed G(M2) and G(M1), whereas only SCLCs expressed b-series gangliosides, such as G(D2), G(D1b), and G(T1b). Accordingly, many SCLC cell lines showed up-regulation of the G(D3) synthase gene. Consequently, we introduced G(D3) synthase cDNA into a SCLC line with low expression of b-series gangliosides and analyzed the effects of newly expressed gangliosides on tumor phenotypes. The transfectant cells expressing high levels of G(D2) and G(D3) exhibited markedly increased growth rates and strongly enhanced invasion activities. Addition of anti-G(D2) monoclonal antibodies into the culture medium of these cells resulted in the marked growth suppression of G(D2)-expressing cell lines with reduced activation levels of mitogen-activated protein kinases but not of nonexpressants, suggesting that G(D2) plays important roles in cell proliferation. Moreover, G(D2)-expressing cells treated with anti-G(D2) antibodies showed features of apoptotic cell death at 30 min after addition of antibodies, i.e., shrinkage of cytoplasm, binding of Annexin V, and staining with propidium iodide, followed by DNA fragmentation. This G(D2)-mediated apoptosis was associated with caspase-3 activation and partly inhibited by a caspase inhibitor, z-Val-Ala-Asp-fluoromethyl ketone. The finding that anti-G(D2) antibodies suppressed the cell growth and induced apoptosis of SCLC cells strongly suggested the usefulness of G(D2) as a target for the therapy of disastrous cancer, although the precise mechanisms for apoptosis remain to be clarified.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11358851

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  71 in total

Review 1.  Sialyltransferases in cancer.

Authors:  F Dall'Olio; M Chiricolo
Journal:  Glycoconj J       Date:  2001 Nov-Dec       Impact factor: 2.916

2.  GD2 expression is closely associated with neuronal differentiation of human umbilical cord blood-derived mesenchymal stem cells.

Authors:  Hye Jin Jin; Hae Yun Nam; Yun Kyong Bae; Soo Yeon Kim; I Rang Im; Wonil Oh; Yoon Sun Yang; Soo Jin Choi; Seong Who Kim
Journal:  Cell Mol Life Sci       Date:  2010-02-18       Impact factor: 9.261

3.  The ceramide moiety of disialoganglioside (GD3) is essential for GD3 recognition by the sialic acid-binding lectin SIGLEC7 on the cell surface.

Authors:  Noboru Hashimoto; Shizuka Ito; Akiko Tsuchida; Robiul H Bhuiyan; Tetsuya Okajima; Akihito Yamamoto; Keiko Furukawa; Yuhsuke Ohmi; Koichi Furukawa
Journal:  J Biol Chem       Date:  2019-05-28       Impact factor: 5.157

4.  Structural Basis of GD2 Ganglioside and Mimetic Peptide Recognition by 14G2a Antibody.

Authors:  Irena Horwacik; Przemyslaw Golik; Przemyslaw Grudnik; Michal Kolinski; Michal Zdzalik; Hanna Rokita; Grzegorz Dubin
Journal:  Mol Cell Proteomics       Date:  2015-07-15       Impact factor: 5.911

5.  ST8SIA1 Regulates Tumor Growth and Metastasis in TNBC by Activating the FAK-AKT-mTOR Signaling Pathway.

Authors:  Khoa Nguyen; Yuanqing Yan; Bin Yuan; Abhishek Dasgupta; Jeffrey Sun; Hong Mu; Kim-Anh Do; Naoto T Ueno; Michael Andreeff; V Lokesh Battula
Journal:  Mol Cancer Ther       Date:  2018-09-20       Impact factor: 6.261

Review 6.  Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy.

Authors:  Zulmarie Perez Horta; Jacob L Goldberg; Paul M Sondel
Journal:  Immunotherapy       Date:  2016-09       Impact factor: 4.196

7.  Ganglioside GD3 promotes cell growth and invasion through p130Cas and paxillin in malignant melanoma cells.

Authors:  Kazunori Hamamura; Keiko Furukawa; Takanori Hayashi; Takeshi Hattori; Junji Nakano; Hideyuki Nakashima; Tetsuya Okuda; Hideki Mizutani; Hisashi Hattori; Minoru Ueda; Takeshi Urano; Kenneth O Lloyd; Koichi Furukawa
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-22       Impact factor: 11.205

8.  Neuroblastoma chemotherapy can be augmented by immunotargeting O-acetyl-GD2 tumor-associated ganglioside.

Authors:  S Faraj; M Bahri; S Fougeray; A El Roz; J Fleurence; J Véziers; M D Leclair; E Thébaud; F Paris; S Birklé
Journal:  Oncoimmunology       Date:  2017-09-21       Impact factor: 8.110

Review 9.  In Search of the Long-Desired 'Copernican Therapeutic Revolution' in Small-Cell Lung Cancer.

Authors:  Noemí Reguart; Elba Marin; Jordi Remon; Roxana Reyes; Cristina Teixido
Journal:  Drugs       Date:  2020-02       Impact factor: 9.546

10.  Lewis y antigen is expressed in oral squamous cell carcinoma cell lines and tissues, but disappears in the invasive regions leading to the enhanced malignant properties irrespective of sialyl-Lewis x.

Authors:  Hiroshi Hotta; Kazunori Hamamura; Kyoko Yamashita; Hidenobu Shibuya; Noriyo Tokuda; Noboru Hashimoto; Keiko Furukawa; Noriyuki Yamamoto; Hisashi Hattori; Shinya Toyokuni; Minoru Ueda; Koichi Furukawa
Journal:  Glycoconj J       Date:  2012-12-15       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.